Azitra, Inc.
ATR-04
EGFRi-associated rash
Resolved
7days ago
Phase 1 readout · ~ Jun 30, 2026 estimated
What's at stake
Phase 1 trial results for ATR-04 in EGFRi-associated rash are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Topline data from first cohort of Phase 1/2 trial expected around mid-2026.”